Skip to main content
Banner background

Convenient oral dosing, with or without food2

RECOMMENDED STARTING DOSE:
400 mg twice daily


AM: two 200-mg tablets

Two 200-mg tablets

Not actual size.
 


PM: two 200-mg tablets

Two 200-mg tablets

Not actual size.
 

  • TABRECTA® (capmatinib) tablets can be taken with or without food

  • Swallow TABRECTA® (capmatinib) tablets whole. Do not break, crush, or chew the tablets

  • If a patient misses or vomits a dose, instruct the patient not to make up the dose, but to take the next dose as its scheduled time

Dosing can be modified to manage adverse reactions2

FIRST DOSE REDUCTION:
300 mg twice daily

SECOND DOSE REDUCTION:
200 mg twice daily


AM: two 150-mg tablets

Two 150-mg tablets

PM: two 150-mg tablets

Two 150-mg tablets

Not actual size.
 


AM: one 200-mg tablet

One 200-mg tablet

PM: one 200-mg tablet

One 200-mg tablet

Not actual size.
 

  • Permanently discontinue TABRECTA® (capmatinib) tablets in patients who are unable to tolerate 200 mg orally twice daily

  • Patients with mild to moderate renal impairment do not require dose modifications 

TABRECTA® (capmatinib) tablets is available in 2 strengths2

One 200-mg tablet

200 mg
NDC 0078-0716-56


Not actual size.
 

One 150-mg tablet

150 mg
NDC 0078-0709-56


Not actual size.
 

How to prescribe TABRECTA® (capmatinib) tablets2

Rx pad

TABRECTA 200 mg 
Take 2 tablets PO bid
Disp 28-day supply

Storage and handling2

  • Dispense in the original package with the desiccant cartridge

  • Store at room temperature* and protect from moisture

  • Discard any unused TABRECTA® (capmatinib) tablets remaining after 6 weeks of first opening the bottle

*20°C to 25°C (68°F-77°F), excursions permitted between 15°C and 30°C (59°F-86°F) [see USP Controlled Room Temperature].
Safety, Dosing, and Administration Guide PDF

TABRECTA Safety, Dosing, and Administration Guide

Explore the safety profile of TABRECTA® (capmatinib) tablets, including dose modification guidance. An informational sheet for patients is also included.
Download

Important Safety Information

Interstitial Lung Disease (ILD)/Pneumonitis. ILD/pneumonitis, which can be fatal, occurred in patients treated with TABRECTA. ILD/pneumonitis occurred in 4.8% of patients treated with TABRECTA in the GEOMETRY mono-1 study, with 1.9% of...

Indication

TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION